EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective

Martin J van den Bent iD, Timothy F Cloughesy iD, Benjamin M Ellingson iD, Joshua E Allen, Samuel C Blackman iD, Mark W Kieran, Joerg C Tonn iD, Philipp Karschnia iD, Maarten Wijnenga iD, Johan Pallud iD, Robert J Young iD, Raymond Y Huang iD und 8 weitere

Neuro-Oncology · 01.10.2025 · 27 (10) · 2514-2523

DOI: 10.1093/neuonc/noaf173 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 19.07.2025. Verfasst von Martin J van den Bent und 19 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Response Assessment in NeuroOncology (RANO) criteria for response to treatment in glioma make a distinction between enhancing and unenhancing tumors, which reflects assessment of a different biological process underlying the magnetic resonance imaging findings in enhancing and nonenhancing tumors. The recent regulatory approval of tovorafenib has also considered the patients with minor responses (25%-50% decrease) based on the 2D measurement on T2/FLAIR MR imaging while incorporating other measures of patient benefit. The INDIGO placebo controlled trial led to the regulatory approval of vorasidenib based on the increase in PFS in the active treatment arm, as measured by blinded independent radiology review using the 2D RANO criteria. With that, more insight in the regulatory requirements for approval in low-grade tumors has been obtained, but other issues in assessing outcome in studies on low-grade enhancing tumors remain. These include the added value of volumetric assessment instead of 2D assessments, and assessment of tumor growth rate as an early marker of outcome. This manuscript gives an overview of the current perspective on and challenges of assessing outcome in trials on unenhancing glioma, with both regulatory and clinical perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsHumansNeoplasm GradingClinical Trials as TopicMagnetic Resonance Imaging

Stichwörter der Autor:innen

RANOminor responsetumor growth rateunenhancing tumorsvolumetric (3D) assessment

Autor:innen und Institutionen

  • Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Chimerix, Jazz Pharmaceuticals Company, Durham, North Carolina.
  • Google Ventures, Mountain View, California.
  • Day One Biopharmaceuticals, Brisbane, California.

ORCID-Profile: Martin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, Samuel C Blackman, Joerg C Tonn, Philipp Karschnia, Maarten Wijnenga, Johan Pallud, Robert J Young, Raymond Y Huang, Ingo K Mellinghoff, John de Groot, Anouk van der Hoorn, Gilbert Youssef, Shawn L Hervey-Jumper, Patrick Y Wen

Förderung

  • NCI NIH HHS

Zitieren

APA

van den Bent, M. J., Cloughesy, T. F., Ellingson, B. M., Allen, J. E., Blackman, S. C., Kieran, M. W., Tonn, J. C., Karschnia, P., Wijnenga, M., Pallud, J., Young, R. J., Huang, R. Y., Mellinghoff, I. K., de Groot, J., van der Hoorn, A., Youssef, G., Hervey-Jumper, S. L., Vogelbaum, M. A., Chang, S. M., & Wen, P. Y. (2025). The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective. Neuro-Oncology, 27(10), 2514-2523. https://doi.org/10.1093/neuonc/noaf173

Vancouver

van den Bent MJ, Cloughesy TF, Ellingson BM, Allen JE, Blackman SC, Kieran MW, et al. The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective. Neuro-Oncology. 2025;27(10):2514-2523. doi:10.1093/neuonc/noaf173

BibTeX
@article{vandenBent2025,
  author = {van den Bent, Martin J and Cloughesy, Timothy F and Ellingson, Benjamin M and Allen, Joshua E and Blackman, Samuel C and Kieran, Mark W and Tonn, Joerg C and Karschnia, Philipp and Wijnenga, Maarten and Pallud, Johan and Young, Robert J and Huang, Raymond Y and Mellinghoff, Ingo K and de Groot, John and van der Hoorn, Anouk and Youssef, Gilbert and Hervey-Jumper, Shawn L and Vogelbaum, Michael A and Chang, Susan M and Wen, Patrick Y},
  title = {The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {10},
  pages = {2514--2523},
  doi = {10.1093/neuonc/noaf173}
}
Kostenlos starten →